Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Napabucasin with FOLFIRI versus napabucasin alone or best supportive care in previously treated metastatic colorectal cancer
2020-000613-32Phase 3Active
- Sponsor
- 1Globe Health Institute
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of napabucasin in metastatic colorectal adenocarcinoma (mCRC) (3 arms), sponsored by 1Globe Health Institute. Primary endpoint: Overall survival. Started Apr 2024; status: active.
02
Drugs
napabucasin
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2020-000613-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000613-32.